Vifor Pharma appoints Colin Bond as Chief Financial Officer
Tuesday, 10 May 2016, ↓ directly to download
Vifor Pharma today announced the appointment of Colin Bond as Chief Financial Officer. Mr. Bond joins Vifor Pharma from Evotec AG and has extensive experience in the running of international, publicly-listed growth companies. He will report directly to the CEO of Vifor Pharma, Søren Tulstrup. Alex Sigalas, Head of Finance and Administration will work in support of Mr. Bond as Vifor Pharma prepares to become an independent specialty pharmaceutical company.
Mr. Bond has been CFO and a member of the Management Board of Evotec since 2010. He has more than 25 years of experience in leading finance positions and has served as CFO of Novelis Europe, CFO of Jet Aviation Group and CFO (EMEA) for Ecolab. During his early career he worked as a pharmacist, auditor and management consultant for Procter & Gamble, Arthur Andersen and PricewaterhouseCoopers, respectively.
He is a qualified chartered accountant and pharmacist, a Fellow of the Institute of Chartered Accountants in England and Wales and a member of the Royal Pharmaceutical Society of Great Britain. He received his MBA from London Business School. He is also a Board member and Head of the Audit Committee of Siegfried Holding AG, a company quoted on the Swiss Stock Exchange.
Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.
Friday, 23 December 2016
Wednesday, 7 December 2016
Thursday, 24 November 2016
Tuesday, 25 October 2016